Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Azacitidine and Enasidenib in Treating Patients with IDH2-Mutant Myelodysplastic Syndrome
      Description

      This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaIDH2 Gene MutationMyelodysplastic Syndrome with Excess BlastsRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic Syndrome
      Talk to us
      COMPLETED
      Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
      Description

      This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2Myelodysplastic Syndrome
      Talk to us
      TERMINATED
      Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
      Description

      This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Blasts Under 15 Percent of Bone Marrow Nucleated CellsBlasts Under 15 Percent of Peripheral Blood White CellsBlasts Under 30 Percent of Bone Marrow Nucleated CellsBlasts Under 30 Percent of Peripheral Blood White CellsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      Talk to us
      COMPLETED
      DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
      Description

      This phase I trial studies the side effects of DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, decitabine, and nivolumab in treating patients with myelodysplastic syndrome or acute myeloid leukemia. DEC-205/NY-ESO-1 fusion protein CDX-1401 is a vaccine that may help the immune system specifically target and kill cancer cells. Poly ICLC may help stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Giving DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, decitabine, and nivolumab may work better in treating patients with myelodysplastic syndrome or acute myeloid leukemia.

      Conditions
      Acute Myeloid LeukemiaBlasts 30 Percent or Less of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeRefractory Anemia
      Talk to us